Baidu
map

16张精美图片:局部晚期非小细胞肺癌放疗靶区勾画

2021-10-12 MedSci原创 MedSci原创

病例信息

病例信息

 

基本信息:52岁,女性,右肺占位一周。

诊断:右肺上叶低分化腺癌ⅢA期。

治疗经过:PET-CT示:右肺上叶后段不规则肿物,4.3cm✖2.5cm,伴代谢增高,右肺门及纵横(2R、3A、4R、7区)多发肿大淋巴结伴代谢增加,考虑转移。支气管镜活检病理:低分化腺癌。

免疫组化:CK18(3+),TTF1(3+),CK5/6(-)EGFR(2+)。放疗靶区:右侧上叶肿物,右肺门,纵隔2R、3A、4R、7区淋巴结引流区。体位:仰卧位热塑体膜固定,双手保肘置于额前,体表标记:体中线第7胸椎水平。

参考文献:

[1]袁双虎,宋启斌主编.肿瘤精准放疗靶区勾画图谱[M].武汉:湖北科学技术出版社.2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770138, encodeId=a2521e7013844, content=<a href='/topic/show?id=bb2a9988363' target=_blank style='color:#2F92EE;'>#靶区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99883, encryptionId=bb2a9988363, topicName=靶区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c98838143713, createdName=lishiwen, createdTime=Tue Sep 13 09:30:48 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060032, encodeId=791c206003254, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 02 03:30:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed Nov 10 06:30:48 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633100, encodeId=66b71633100ea, content=<a href='/topic/show?id=1dc699884a9' target=_blank style='color:#2F92EE;'>#靶区勾画#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99884, encryptionId=1dc699884a9, topicName=靶区勾画)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d3222012495, createdName=周虎, createdTime=Mon Apr 11 01:30:48 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406103, encodeId=a1911406103b2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Oct 14 04:30:48 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059756, encodeId=f1841059e568b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue Oct 12 13:33:51 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2022-09-13 lishiwen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770138, encodeId=a2521e7013844, content=<a href='/topic/show?id=bb2a9988363' target=_blank style='color:#2F92EE;'>#靶区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99883, encryptionId=bb2a9988363, topicName=靶区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c98838143713, createdName=lishiwen, createdTime=Tue Sep 13 09:30:48 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060032, encodeId=791c206003254, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 02 03:30:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed Nov 10 06:30:48 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633100, encodeId=66b71633100ea, content=<a href='/topic/show?id=1dc699884a9' target=_blank style='color:#2F92EE;'>#靶区勾画#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99884, encryptionId=1dc699884a9, topicName=靶区勾画)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d3222012495, createdName=周虎, createdTime=Mon Apr 11 01:30:48 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406103, encodeId=a1911406103b2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Oct 14 04:30:48 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059756, encodeId=f1841059e568b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue Oct 12 13:33:51 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770138, encodeId=a2521e7013844, content=<a href='/topic/show?id=bb2a9988363' target=_blank style='color:#2F92EE;'>#靶区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99883, encryptionId=bb2a9988363, topicName=靶区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c98838143713, createdName=lishiwen, createdTime=Tue Sep 13 09:30:48 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060032, encodeId=791c206003254, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 02 03:30:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed Nov 10 06:30:48 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633100, encodeId=66b71633100ea, content=<a href='/topic/show?id=1dc699884a9' target=_blank style='color:#2F92EE;'>#靶区勾画#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99884, encryptionId=1dc699884a9, topicName=靶区勾画)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d3222012495, createdName=周虎, createdTime=Mon Apr 11 01:30:48 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406103, encodeId=a1911406103b2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Oct 14 04:30:48 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059756, encodeId=f1841059e568b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue Oct 12 13:33:51 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770138, encodeId=a2521e7013844, content=<a href='/topic/show?id=bb2a9988363' target=_blank style='color:#2F92EE;'>#靶区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99883, encryptionId=bb2a9988363, topicName=靶区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c98838143713, createdName=lishiwen, createdTime=Tue Sep 13 09:30:48 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060032, encodeId=791c206003254, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 02 03:30:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed Nov 10 06:30:48 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633100, encodeId=66b71633100ea, content=<a href='/topic/show?id=1dc699884a9' target=_blank style='color:#2F92EE;'>#靶区勾画#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99884, encryptionId=1dc699884a9, topicName=靶区勾画)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d3222012495, createdName=周虎, createdTime=Mon Apr 11 01:30:48 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406103, encodeId=a1911406103b2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Oct 14 04:30:48 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059756, encodeId=f1841059e568b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue Oct 12 13:33:51 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1770138, encodeId=a2521e7013844, content=<a href='/topic/show?id=bb2a9988363' target=_blank style='color:#2F92EE;'>#靶区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99883, encryptionId=bb2a9988363, topicName=靶区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c98838143713, createdName=lishiwen, createdTime=Tue Sep 13 09:30:48 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060032, encodeId=791c206003254, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 02 03:30:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed Nov 10 06:30:48 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633100, encodeId=66b71633100ea, content=<a href='/topic/show?id=1dc699884a9' target=_blank style='color:#2F92EE;'>#靶区勾画#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99884, encryptionId=1dc699884a9, topicName=靶区勾画)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d3222012495, createdName=周虎, createdTime=Mon Apr 11 01:30:48 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406103, encodeId=a1911406103b2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Oct 14 04:30:48 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059756, encodeId=f1841059e568b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue Oct 12 13:33:51 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-14 chg122
  6. [GetPortalCommentsPageByObjectIdResponse(id=1770138, encodeId=a2521e7013844, content=<a href='/topic/show?id=bb2a9988363' target=_blank style='color:#2F92EE;'>#靶区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99883, encryptionId=bb2a9988363, topicName=靶区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c98838143713, createdName=lishiwen, createdTime=Tue Sep 13 09:30:48 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060032, encodeId=791c206003254, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 02 03:30:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed Nov 10 06:30:48 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633100, encodeId=66b71633100ea, content=<a href='/topic/show?id=1dc699884a9' target=_blank style='color:#2F92EE;'>#靶区勾画#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99884, encryptionId=1dc699884a9, topicName=靶区勾画)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d3222012495, createdName=周虎, createdTime=Mon Apr 11 01:30:48 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406103, encodeId=a1911406103b2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Oct 14 04:30:48 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059756, encodeId=f1841059e568b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue Oct 12 13:33:51 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 站在塔尖

    学习

    0

相关资讯

NEJM:ADC药物治疗非小细胞肺癌临床试验,效果显著

2021年9月18日,美国 Dana-Farber 癌症研究所的研究人员在国际四大医学期刊之首的《新英格兰医学期刊》(NEJM)上发表了题为:Trastuzumab Deruxtecan in HER

BP:中医药可辅助治疗肺癌

肺癌是世界范围内严重威胁人类健康的癌症相关死亡的主要原因,其中非小细胞肺癌(NSCLC)约占所有亚型的85%。NSCLC的规范治疗以手术、放疗、化疗、靶向治疗、免疫治疗等为基础,取得了非凡的临床效果。

肺部出现磨玻璃结节该如何判断?牢记这8点!

原发性支气管肺癌(简称肺癌)是全球常见,目前发病率及死亡率最高的恶性肿瘤之一

直播:上海市胸科医院张波全面解读:EGFR突变晚期非小细胞肺癌的诊疗进展

🔥 9月17日19:30直播 | 免费报名,还可0元申领《肺癌的治疗方案与临床研究》等12本好书📕

早期非小细胞肺癌射波刀靶区勾画

手把手教你学会早期非小细胞肺癌射波刀靶区勾画

Baidu
map
Baidu
map
Baidu
map